Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to <100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND
Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Heinz Gisslinger(Medical University of Vienna), Jean‐Jacques Kiladjian(Délégation Paris 5), Guangsheng He(Jiangsu Province Hospital), Minghui Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Dietger Niederwieser(Leipzig University of Applied Sciences), Fiorenza Barraco(Hôpital Lyon Sud), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Monika Wroclawska(Novartis (Switzerland)), Divyadeep Karumanchi(Gilead Sciences (United States)), Peter A.W. te Boekhorst(Erasmus MC), Pantelia Roussou(Novartis (Switzerland)), Anna Marina Liberati(University of Perugia), Srđan Verstovšek(Unknown), Ling Pan(Sichuan University), Françoise Boyer(Centre Hospitalier Universitaire d'Angers), Ester Pungolino(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Haitao Meng(First Affiliated Hospital Zhejiang University), Karen Sinclair(Novartis (Switzerland))
Cited by 11
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k